Healthcare Industry News: U.S. Food and Drug Administration
News Release - March 14, 2018
Pharmaceutical Startup, Bridge Therapeutics, Announces Tim Peara Will Be Joining the Company as the Director of FinanceBIRMINGHAM, Ala., March 14, 2018 -- (Healthcare Sales & Marketing Network) -- The innovative late development-stage pharmaceutical startup, Bridge Therapeutics® has announced Tim Peara will be joining its management team as the new Director of Finance, effective immediately.
Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for companies in finance, energy tech, and industry.
Throughout his career, Peara has contributed directly to the growth and strategy of industry leaders, including Wells Fargo, Prudential, Lehman Brothers, Koch Industries, GE, Bechtel and United Technologies. Peara has also built and led teams while consulting to a variety of businesses.
Peara holds a BA in Latin American Studies from Wesleyan University in Connecticut and an MBA in Finance & International Business from the University of Chicago's Booth School of Business.
Bridge Therapeutics - based in Birmingham, Alabama - is aggressively researching chronic pain alternatives to help reduce the impact of the opioid epidemic. The pharma company is currently pursuing FDA and European Medicines Agency (EMA) approval of a patented drug combination for the treatment of chronic pain in opioid-experienced patients.
"I believe Bridge Therapeutics is well positioned to provide safer alternatives that will help curb this current opioid epidemic," said Peara. "I've worked with many industry titans and I've followed the rapid growth of Bridge Therapeutics. It's even more exciting to work with Bridge Therapeutics on bringing their patented chronic pain medications to the market."
Bridge Therapeutics is currently working to bring new chronic pain medications to the market. Their investigational drug, BT-205, is a unique combination of two synergistic chronic pain drugs - the partial-agonist opioid buprenorphine and the NSAID meloxicam - delivered in a state-of-the-art sublingual formulation. This dosing and delivery method is commercially advantageous over current chronic pain alternatives.
Roughly 70 million Americans consume opioids monthly, and more than 17 million Americans take them daily, according to the National Institute on Drug Abuse. More than 2 million Americans suffer from substance abuse disorders related to prescription opioid pain relievers, according to the National Institute on Drug Abuse. BT-205 has the potential to address this growing epidemic as a viable drug alternative for those already taking opioids.
The Chief Operating Officer for Bridge Therapeutics, David H. Bergstrom, Ph.D., says Peara's experience with industry, energy technology and finance will have an immediate positive impact on their company.
"Peara brings an extensive understanding of finance, institutional investments, and technology to Bridge Therapeutics," said Dr. Bergstrom. "Our board is looking forward to working closely with Mr. Peara as we enter a new phase for our research and development and, commercialization of chronic pain medication alternatives."
About Bridge Therapeutics
Bridge Therapeutics® is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics' goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and unsatisfactory. For more information, visit www.bridgetherapeutics.com or email email@example.com.
Source: Bridge Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.